These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Zucker S; Cao J; Chen WT Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650 [TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Vihinen P; Kähäri VM Int J Cancer; 2002 May; 99(2):157-66. PubMed ID: 11979428 [TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment. Yang JS; Lin CW; Su SC; Yang SF Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787 [TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase inhibitors: applications in oncology. Yip D; Ahmad A; Karapetis CS; Hawkins CA; Harper PG Invest New Drugs; 1999; 17(4):387-99. PubMed ID: 10759405 [TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review). Duffy MJ; McCarthy K Int J Oncol; 1998 Jun; 12(6):1343-8. PubMed ID: 9592197 [TBL] [Abstract][Full Text] [Related]
8. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Jones L; Ghaneh P; Humphreys M; Neoptolemos JP Ann N Y Acad Sci; 1999 Jun; 880():288-307. PubMed ID: 10415874 [TBL] [Abstract][Full Text] [Related]
12. Tissue inhibitors of matrix metalloproteinases in cancer. Blavier L; Henriet P; Imren S; Declerck YA Ann N Y Acad Sci; 1999 Jun; 878():108-19. PubMed ID: 10415723 [TBL] [Abstract][Full Text] [Related]
13. Clinical studies with matrix metalloproteinase inhibitors. Brown PD APMIS; 1999 Jan; 107(1):174-80. PubMed ID: 10190295 [TBL] [Abstract][Full Text] [Related]
14. The role of tissue inhibitor of metalloproteinase-1 in specific aspects of cancer progression and reproduction. Khokha R; Waterhouse P J Neurooncol; 1994; 18(2):123-7. PubMed ID: 7525887 [TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase inhibitors as anticancer agents. Konstantinopoulos PA; Karamouzis MV; Papatsoris AG; Papavassiliou AG Int J Biochem Cell Biol; 2008; 40(6-7):1156-68. PubMed ID: 18164645 [TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase inhibitors. Brown PD Breast Cancer Res Treat; 1998; 52(1-3):125-36. PubMed ID: 10066077 [TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Rasmussen HS; McCann PP Pharmacol Ther; 1997; 75(1):69-75. PubMed ID: 9364582 [TBL] [Abstract][Full Text] [Related]
18. Preclinical and clinical studies of MMP inhibitors in cancer. Drummond AH; Beckett P; Brown PD; Bone EA; Davidson AH; Galloway WA; Gearing AJ; Huxley P; Laber D; McCourt M; Whittaker M; Wood LM; Wright A Ann N Y Acad Sci; 1999 Jun; 878():228-35. PubMed ID: 10415734 [TBL] [Abstract][Full Text] [Related]
19. Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects. Wong MS; Sidik SM; Mahmud R; Stanslas J Clin Exp Pharmacol Physiol; 2013 May; 40(5):307-19. PubMed ID: 23534409 [TBL] [Abstract][Full Text] [Related]
20. Unraveling galectin-1 as a novel therapeutic target for cancer. Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Neuzillet C; Albert S; Raymond E; Faivre S Cancer Treat Rev; 2014 Mar; 40(2):307-19. PubMed ID: 23953240 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]